HomeNDC LookupIngredientsBisacodyl › 00574-7050-50
Bisacodyl 10 mg Suppository, 50 suppositories — NDC 00574-7050-50 package photo

Bisacodyl 10 mg Suppository, 50 suppositories

by Padagis US LLC · 50 BLISTER PACK in 1 CARTON (0574-7050-50) / 1 SUPPOSITORY in 1 BLISTER PACK
NDC 00574-7050-50
🏷️ FDA NDC (as labeled) 0574-7050-50 billing pads the labeler segment with a zero
This package
Contains50 suppositories Cost per ea$0.3207 NADAC Per package$16.04 / 50 suppository Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.6565/unit — full pricing hub ↓
OTC On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 0574-7050-50
Product NDC 0574-7050
11-digit billing NDC 00574705050
NCPDP billing unit EA — each (per item)
RxCUI 198509
UNII 10X0709Y6I
Application # M007
SPL Set ID 7eada0fc-5f83-43da-a56f-b0f537298208
Established class (EPC) Stimulant Laxative
Physiologic effect Increased Large Intestinal Motility; Stimulation Large Intestine Fluid/Electrolyte Secretion
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1990-09-01
Route RECTAL
Dosage form SUPPOSITORY
Substance BISACODYL
GPI-14 46200010005205
GPI class Bisacodyl
GCN Seq No 002944
GCN 08731
HICL code 001301
Ingredient (HICL) Bisacodyl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q3
Therapeutic class — intermediate (HIC2) Anal-Rectal Preparations
HIC3 code Q3S
Therapeutic class — specific (HIC3) Laxatives, Local/Rectal
AHFS code 56:12.00.00
AHFS class Cathartics And Laxatives
FDB label name BISACODYL 10 MG SUPPOSITORY
FDB brand name Bisacodyl
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 0574-7050-50 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00574-7050-50. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Stimulant Laxative class.

Pharmacologic class Stimulant Laxative
Drug family (ATC) Contact laxatives, Enemas
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerPadagis US LLC
FDA applicationM007 (OTC MONOGRAPH DRUG)
Labeler code00574
First marketedSep 1990
Product typeHuman Otc Drug
Portfolio63 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name BISACODYL 10 MG SUPPOSITORY Ingredient Bisacodyl
📖 What it is MedlinePlus · NLM

Rectal bisacodyl is used on a short-term basis to treat constipation. It also is used to empty the bowels before surgery and certain medical procedures. Bisacodyl is in a class of medications called stimulant laxatives. It works by increasing activity of the intestines to cause a bowel movement.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on which form you're using. Oral tablets (like Dulcolax Stimulant Laxative) usually take 6 to 12 hours, so many people take them at bedtime and get results in the mornin...
  • No — it's really important not to chew, crush, or break bisacodyl tablets. They have a special protective coating that helps them reach the right part of your gut without irritatin...
  • Can I chew or crush the tablet if I have trouble swallowing?
  • Milk and antacids can break down the protective coating on bisacodyl tablets too soon, before the medicine reaches where it needs to work. This can cause stomach irritation and mak...
📖 Read our full Bisacodyl guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color White
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII FM8D1RE2VP
    A plant-based oil that has been chemically hardened to stay solid at room temperature. It works as a binder and lubricant to hold tablet ingredients together and help them release properly during digestion.

1 inactive ingredient listed in the exact product block matched to this NDC.

The official label also stateshydrogenated palm kernel oil

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.321 $16.04 / 50 suppository
Medicaid paysCMS SDUD · 12 mo $0.6565 $32.83 / 50 suppository
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.369 $0.241
▲ Up 29% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Bisacodyl 10 mgthis 00574-7050-50 Padagis 50 suppositories $0.321 Availability likely
Bisacodyl 10 mg 00904-7142-12 Major 12 suppositories $0.321 Availability likely
Good Neighbor Pharmacy Gentle Laxative 10 mg/2000mg 46122-0608-51 AmerisourceBergen 40 mg $0.321 Availability likely
Bisacodyl 10 mg 57237-0327-03 Rising 30 suppositories $0.321 Availability likely
Proctozone-B 10 mg 57237-0337-03 Rising 30 suppositories $0.321 Availability likely
Bisacodyl 10 mg 70000-0573-01 Cardinal 4 suppositories $0.321 Availability likely
Foster and Thrive Gentle Laxative 10 mg/2000mg 70677-1091-01 Strategic 40 mg $0.321 Availability likely
Walgreens Gentle Laxative 10 mg 00363-0466-04 Walgreens 40 mg FDA listed
Walgreens Gentle Laxative 10 mg 00363-0468-04 Walgreens 4 suppositories FDA listed
Rite-Aid Gentle Laxative 10 mg 11822-4890-05 RITE 8 suppositories FDA listed
Gentle Laxative Bisacodyl 10 mg 13709-0321-01 NeilMed 30 capsules FDA listed
Bisacodyl Laxative 10 mg/1.8g 13709-0328-01 Neilmed 1.8 g FDA listed
HEB Gentle Laxative 10 mg/2000mg 37808-0877-08 H 40 mg FDA listed
Dulcolax Laxative 10 mg 41167-0210-01 Chattem, 4 suppositories FDA listed
Meijer Gentle Laxative 10 mg/2000mg 41250-0665-04 Meijer 40 mg FDA listed
Discount Drugmart Gentle Laxative 10 mg/2000mg 53943-0805-08 Discount 40 mg FDA listed
Dollar General Gentle Laxative 10 mg/2000mg 55910-0457-04 Dolgencorp, 40 mg FDA listed
Bisacodyl 10 mg 57896-0443-01 GERI-CARE 100 suppositories FDA listed
Stratuscare Bisacodyl 10 mg 58980-0415-04 Stratus 4 suppositories FDA listed
CVS Gentle Laxative 10 mg 59779-0107-09 CVS 8 suppositories FDA listed
Bisacodyl 10 mg 68016-0084-08 Pharmacy 8 suppositories FDA listed
Bisacodyl 10 mg 69842-0816-04 CVS 4 suppositories FDA listed
Laxative 10 mg 70795-1010-01 GRAXCELL 100 suppositories FDA listed
OneLAX 10 mg 71399-8460-02 AKRON 12 suppositories FDA listed
Conlax 10 mg 72701-0102-04 Bliss 4 suppositories FDA listed
Bisacodyl 10 mg 82568-0028-02 AARNA 12 suppositories FDA listed
Bisacodyl 10 mg 83720-0550-25 Oncor 12 suppositories FDA listed
Bisacodyl Laxative 10 mg 71457-0501-01 InvaDerm 102 suppositories FDA listed
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1990
On the market since
Sep 1990
📍
2026
Currently FDA-listed
36 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 00574-7050-50, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
57.7K
Units reimbursed last 4 qtrs
1M
Gross reimbursed last 4 qtrs
$674.7K
Avg / prescription
$11.69
Avg / unit
$0.6565
Latest quarter Q4 2025
15.2KRx
Medicaid pays / ea
$0.6565
gross reimbursed
vs
NADAC / ea
$0.3207
acquisition cost
=
Spread
+$0.3358
+105% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
64% FFS 36% MCO
Fee-for-service · 36,840 Rx Managed care · 20,886 Rx
State Medicaid map
Alaska: no data reported AK Maine: 6,075 units · 435 per 100k residents ME Washington: 92,362 units · 1,182 per 100k residents WA Idaho: no data reported ID Montana: 3,538 units · 313 per 100k residents MT North Dakota: no data reported ND Minnesota: 30,054 units · 524 per 100k residents MN Wisconsin: 8,895 units · 151 per 100k residents WI Michigan: 41,646 units · 415 per 100k residents MI New York: 143,089 units · 731 per 100k residents NY Vermont: 2,589 units · 400 per 100k residents VT New Hampshire: 2,174 units · 155 per 100k residents NH Oregon: 31,221 units · 738 per 100k residents OR Nevada: 2,335 units · 73.1 per 100k residents NV Wyoming: 264 units · 45.2 per 100k residents WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 12,968 units · 103 per 100k residents IL Indiana: 68,370 units · 996 per 100k residents IN Ohio: 51,621 units · 438 per 100k residents OH Pennsylvania: 49,847 units · 385 per 100k residents PA New Jersey: 7,273 units · 78.3 per 100k residents NJ Massachusetts: 46,655 units · 666 per 100k residents MA California: 266,395 units · 684 per 100k residents CA Utah: no data reported UT Colorado: 6,150 units · 105 per 100k residents CO Nebraska: 17,275 units · 873 per 100k residents NE Missouri: 24,626 units · 397 per 100k residents MO Kentucky: 30,058 units · 664 per 100k residents KY West Virginia: no data reported WV Virginia: 13,019 units · 149 per 100k residents VA Maryland: 2,249 units · 36.4 per 100k residents MD Connecticut: 8,944 units · 247 per 100k residents CT Rhode Island: 6,744 units · 616 per 100k residents RI Arizona: 20,128 units · 271 per 100k residents AZ New Mexico: 1,270 units · 60.1 per 100k residents NM Kansas: 7,637 units · 260 per 100k residents KS Arkansas: 1,632 units · 53.2 per 100k residents AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: 4,281 units · 415 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 118 units · 1.1 per 100k residents GA D.C.: 1,789 units · 263 per 100k residents DC Hawaii: 14,341 units · 999 per 100k residents HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
1.11,182
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Washington 1,182 /100k
2 Hawaii 999 /100k
3 Indiana 996 /100k
4 Nebraska 873 /100k
5 Oregon 738 /100k
6 New York 731 /100k
7 California 684 /100k
8 Massachusetts 666 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 suppository this page00574-7050-50 57,726 Rx · $674,679
1 suppository00574-7050-12 49,121 Rx · $571,148
Drug total (last 4 qtrs): 106,847 Rx · 1,884,760 units · $1,245,827 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
00574-7050-12 12 BLISTER PACK in 1 CARTON (0574-7050-12) / 1 SUPPOSITORY in 1 BLISTER PACK $0.3207 / ea $3.85 1990-09-01 Active
00574-7050-50 You're viewing this 50 BLISTER PACK in 1 CARTON (0574-7050-50) / 1 SUPPOSITORY in 1 BLISTER PACK $0.3207 / ea $16.03 1990-09-01 Active

This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.3207 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 54% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 00574-7050-50?
NDC 00574-7050-50 contains 50 suppositories — 50 blister pack in 1 carton / 1 suppository in 1 blister pack.
What is the difference between NDC 00574-7050-50 and NDC 00574-7050-12?
Both are Bisacodyl 10 mg Suppository — the drug itself is identical. NDC 00574-7050-50 is the 50 suppositories package, while NDC 00574-7050-12 is the 12 suppositories package.
What NDC number is used to bill for this package of Bisacodyl 10 mg Suppository?
Bill NDC 00574-7050-50 — the 11-digit billing format is 00574705050. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 23 words

Use • for temporary relief of occasional constipation and irregularity • this product generally produces bowel movement in 15 minutes to 1 hour

⏱️ Dosage and Administration 58 words

Directions adults and children 12 years of age and over 1 suppository in a single daily dose. Pull apart foil. Insert suppository well into rectum, pointed end first. Retain about 15 to 20 minutes. children 6 to under 12 years of age ½ suppository in a single daily dose children under 6 years of age ask a doctor

⚠️ Warnings 123 words

Warnings For rectal use only Ask a doctor before use if you have • stomach pain, nausea or vomiting • a sudden change in bowel habits that lasts more than 2 weeks Ask a doctor or pharmacist before use if you are taking any other drug. Take this product two or more hours before or after other drugs. Laxatives may affect how other drugs work.

When using this product it may cause stomach discomfort, faintness, rectal burning and milk cramps Stop use and ask a doctor if • you have rectal bleeding or fail to have a bowel movement after use of a laxative because this may indicate a serious condition • you need to use a laxative for more than 1 week

📦 Storage and Handling 7 words

Other information • store at 20-25°C (68-77°F)

🧪 Active Ingredient 9 words

Active ingredient (in each suppository) Bisacodyl USP 10 mg

🧪 Inactive Ingredients 6 words

Inactive ingredients hydrogenated palm kernel oil

🎯 Purpose 3 words

Purpose Stimulant laxative

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.